Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + cisplatin + anlotinib + benmelstobart for bladder-preserving treatment of muscle-invasive bladder cancer
ChiCTR2400089661Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Sep 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, cisplatin, anlotinib and benmelstobart in bladder cancer and transitional cell carcinoma of the bladder (TCC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Bladder-intact event-free survival. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
gemcitabinecisplatinanlotinibbenmelstobart
03
Conditions
bladder cancertransitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on ChiCTR2400089661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089661.